Following the FDA approval of linvoseltamab (Lynozyfic; Regeneron) for heavily pretreated multiple myeloma, Sundar Jagannath, MBBS, highlights its potential for earlier use, increased accessibility, ...

The newly FDA-approved linvoseltamab (Lynozyfic; Regeneron) may improve access to multiple myeloma treatment by offering an off-the-shelf, outpatient option that can be administered in community ...

Dr. Jagannath is a distinguished oncologist who is renowned for his groundbreaking contributions to the field of multiple myeloma,” said Syed Rizvi, MD, Caribou’s chief medical officer. “Dr.

If you were to meet Dr. Sundar Jagannath in a crowded room (not that we have those anymore in the COVID-19 era), you would not assume that not only is he one of the greatest myeloma docs of all time, ...

News provided by Caribou Biosciences, Inc. Nov 06, 2023, 8:00 AM ET -- Dr. Jagannath is a renowned expert in the research and treatment of multiple myeloma -- ...

--Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Sundar Jagannath, MD, to its scientific advisory board.